FDA de­lays Sarep­ta's Duchenne gene ther­a­py de­ci­sion by a month

The FDA de­layed its de­ci­sion whether to grant ac­cel­er­at­ed ap­proval to Sarep­ta Ther­a­peu­tics’ gene ther­a­py for Duchenne mus­cu­lar dy­s­tro­phy, push­ing it back about one month to June 22.

Sarep­ta an­nounced the de­lay in a news re­lease on Wednes­day morn­ing, say­ing the FDA needs “mod­est ad­di­tion­al time to com­plete the re­view, in­clud­ing fi­nal la­bel ne­go­ti­a­tions and post-mar­ket­ing com­mit­ment dis­cus­sions.”

The com­pa­ny’s stock tum­bled about 9% in trad­ing on Wednes­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER